Published in Ann Intern Med on October 15, 1995
Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods. J Clin Microbiol (2001) 1.49
The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.09
Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group. Eur J Clin Microbiol Infect Dis (1997) 0.75
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS (1997) 9.08
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med (1999) 7.28
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA (1998) 6.69
Barriers to use of free antiretroviral therapy in injection drug users. JAMA (1998) 6.67
Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (1995) 5.64
The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med (1992) 5.51
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (1996) 5.08
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ (2001) 4.96
Preliminary evaluation of a scheme for grading the gross morphology of the human intervertebral disc. Spine (Phila Pa 1976) (1990) 4.11
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Hospital utilization and costs in a cohort of injection drug users. CMAJ (2001) 3.48
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ (1999) 3.35
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS (1989) 3.19
Decline in deaths from AIDS due to new antiretrovirals. Lancet (1997) 3.13
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Role of Pr160gag-pol in mediating the selective incorporation of tRNA(Lys) into human immunodeficiency virus type 1 particles. J Virol (1994) 2.94
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Practice patterns of family physicians with 2-year residency v. 1-year internship training: do both roads lead to Rome? CMAJ (1989) 2.87
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther (1999) 2.85
In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol (1992) 2.85
Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med (1990) 2.85
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr (2001) 2.80
Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet (1994) 2.78
Changes in sexual behaviour and fear of AIDS. Lancet (1984) 2.76
Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant (2011) 2.69
Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections. J Clin Microbiol (2002) 2.56
Lower socioeconomic status and shorter survival following HIV infection. Lancet (1994) 2.47
Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ (2001) 2.47
Industry-sponsored clinical research: a double-edged sword. Lancet (2001) 2.45
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet (2000) 2.42
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Effects of alterations of primer-binding site sequences on human immunodeficiency virus type 1 replication. J Virol (1994) 2.37
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin Infect Dis (1998) 2.31
Spinal bone loss and ovulatory disturbances. N Engl J Med (1990) 2.31
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob Agents Chemother (1996) 2.31
Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem (1994) 2.28
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med (1997) 2.27
Purification and characterization of S-adenosyl-L-methionine: uroporphyrinogen III methyltransferase from Pseudomonas denitrificans. J Bacteriol (1989) 2.25
Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med (1995) 2.22
Retinopathy of prematurity-induced blindness: birth weight-specific survival and the new epidemic. Pediatrics (1990) 2.18
Burkholderia pseudomallei traced to water treatment plant in Australia. Emerg Infect Dis (2000) 2.15
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS (2001) 2.15
The Vancouver Lymphadenopathy-AIDS Study: 4. Effects of exposure factors, cofactors and HTLV-III seropositivity on number of helper T cells. Can Med Assoc J (1985) 2.11
The role of secondary vaccine failures in measles outbreaks. Am J Public Health (1989) 2.10
Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest (1994) 2.10
Social determinants predict needle-sharing behaviour among injection drug users in Vancouver, Canada. Addiction (1997) 2.06
Use of dried blood spot specimens in the detection of human immunodeficiency virus type 1 by the polymerase chain reaction. J Clin Microbiol (1991) 2.05
The Vancouver Lymphadenopathy-AIDS Study: 6. HIV seroconversion in a cohort of homosexual men. CMAJ (1986) 2.01
Triple-combination antiretroviral therapy in sub-Saharan Africa. Lancet (1997) 2.00
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.99
Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol (2000) 1.96
Prevalence of HIV infection in provincial prisons in British Columbia. CMAJ (1994) 1.96
Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology (1993) 1.94
Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis (1992) 1.94
Genetic and sequence analysis of an 8.7-kilobase Pseudomonas denitrificans fragment carrying eight genes involved in transformation of precorrin-2 to cobyrinic acid. J Bacteriol (1990) 1.92
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 1.86
Determinants of HIV seroconversion in injection drug users during a period of rising prevalence in Vancouver. Int J STD AIDS (1997) 1.85
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol (2000) 1.84
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm Infect (2002) 1.81
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS (1998) 1.81
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. J Infect Dis (1990) 1.73
Surviving the sex trade: a comparison of HIV risk behaviours among street-involved women in two Canadian cities who inject drugs. AIDS Care (2003) 1.69
Quantification of the variation due to laboratory and physiologic sources in CD4 lymphocyte counts of clinically stable HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.68
Mutations in the kissing-loop hairpin of human immunodeficiency virus type 1 reduce viral infectivity as well as genomic RNA packaging and dimerization. J Virol (1997) 1.68
The social determinants of emergency department and hospital use by injection drug users in Canada. J Urban Health (1999) 1.67
Assay, purification, and characterization of cobaltochelatase, a unique complex enzyme catalyzing cobalt insertion in hydrogenobyrinic acid a,c-diamide during coenzyme B12 biosynthesis in Pseudomonas denitrificans. J Bacteriol (1992) 1.67
HIV infection and risk behaviours among young gay and bisexual men in Vancouver. CMAJ (2000) 1.66
Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis (2000) 1.66
The assessment of diagnostic tests. A survey of current medical research. JAMA (1984) 1.65
AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
A 500-kiloton airburst over Chelyabinsk and an enhanced hazard from small impactors. Nature (2013) 1.61
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer (2004) 1.61
Selection of women at high risk of breast cancer for initial screening. J Chronic Dis (1986) 1.60
The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy. Can Med Assoc J (1985) 1.59
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Effects of mutations in Pr160gag-pol upon tRNA(Lys3) and Pr160gag-plo incorporation into HIV-1. J Mol Biol (1997) 1.58
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis (2001) 1.57
Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. Proc Natl Acad Sci U S A (1995) 1.56
HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys (1999) 1.55
Iatrogenic atrioventricular bypass tract following a Fontan operation for tricuspid atresia. Heart (1997) 1.55